Clinical trials
catalyst calendar across sponsors →Studies where INBX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 13 tracked-famous managers (VIKING GLOBAL INVESTORS LP, Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., +8 more) · FINRA short interest 15.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumabRandomized · Single-masked · Treatment | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCNCT06295731Phase 2: Objective Response Rate (ORR)Randomized · Double-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: INBRX-106, Pembrolizumab | Head and Neck Squamous Cell Carcinoma (HNSCC) | 410 | May 2029 | ≤ 1,015 d | 2026-05-08 |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasNCT03715933Frequency and severity of adverse events of INBRX-109Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil | Ewing Sarcoma, Colorectal Adenocarcinoma | 411 | Dec 2028 | ≤ 864 d | 2026-05-22 |
| Study of INBRX-109 in Conventional ChondrosarcomaNCT04950075Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: INBRX-109, Placebo | Conventional Chondrosarcoma | 206 | 2025-09-30actual | — | 2026-07-14 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerNCT03809624Frequency of adverse events of INBRX-105Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Program terminated due to lack of meaningful efficacy signal. | Drug: INBRX-105 - PDL1x41BB antibody, Pembrolizumab | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 160 | 2024-10-03actual | — | 2024-10-23 |
| Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin DeficiencyNCT03815396Frequency of adverse events of INBRX-101Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INBRX-101/rhAAT-Fc | Alpha-1 Antitrypsin Deficiency, AATD | 31 | 2022-08-18actual | — | 2022-09-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19